ASCO 2017: Phase I study of the anti-HGF monoclonal antibody, ficlatuzumab, and cetuximab in cetuximab-resistant, recurrent/metastatic head and neck cancer
Category: Presentation
ASCO 2017: CyFi: A phase I study exploring the role of cMET pathway inhibition with ficlatuzumab (Fi) combined with high-dose cytarabine (Cy) in patients with high risk relapsed or refractory acute myeloid leukemia (AML)
ASCO 2017: CyFi: A phase I study exploring the role of cMET pathway inhibition with ficlatuzumab (Fi) combined with high-dose cytarabine (Cy) in patients with high risk relapsed or refractory acute myeloid leukemia (AML)
ASCO 2017: Tivo-3: A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib hydrochloride to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC)
ASCO 2017: Tivo-3: A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib hydrochloride to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC)
ASCO 2015: Tivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma: final results of a Phase 3 trial (901) and efficacy results of a second line tivozanib extension study (902)
ASCO 2015: Tivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma: final results of a Phase 3 trial (901) and efficacy results of a second line tivozanib extension study (902)
Annual Symposium on Anti-angiogenesis and Immune Therapies for Cancer 2015: Circulating neuropilin-1 as a potential biomarker of progression-free survival benefit for tivozanib in metastatic clear cell renal cell carcinoma (RCC): post-hoc biomarker analysis of tivozanib RCC trials
Annual Symposium on Anti-angiogenesis and Immune Therapies for Cancer 2015: Circulating neuropilin-1 as a potential biomarker of progression-free survival benefit for tivozanib in metastatic clear cell renal cell carcinoma (RCC): post-hoc biomarker analysis of tivozanib RCC trials
ESMO 2014: Efficacy analysis of gefitinib +/- ficlatuzumab in serum proteomic-based subgroups of patients with previously untreated lung adenocarcinoma
ESMO 2014: Efficacy analysis of gefitinib +/- ficlatuzumab in serum proteomic-based subgroups of patients with previously untreated lung adenocarcinoma
ESMO 2014: Phase 2 clinical evaluation of preclinically defined biomarkers for vascular endothelial growth factor tyrosine kinase inhibitor tivozanib in renal cell carcinoma
ESMO 2014: Phase 2 clinical evaluation of preclinically defined biomarkers for vascular endothelial growth factor tyrosine kinase inhibitor tivozanib in renal cell carcinoma
ASCO 2013: Efficacy and safety data from patients with advanced renal cell cancer treated with tivozanib hydrochloride after progression on sorafenib
ASCO 2013: Efficacy and safety data from patients with advanced renal cell cancer treated with tivozanib hydrochloride after progression on sorafenib
ASCO GU 2013: Subgroup analyses of a Phase III trial comparing tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC)
ASCO GU 2013: Subgroup analyses of a Phase III trial comparing tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC)
ASCO GU 2013: Treatment benefit of tivozanib hydrochloride vs sorafenib on health-related quality of life among patients with advanced/metastatic renal cell carcinoma (mRCC): TIVO-1 study results
ASCO GU 2013: Treatment benefit of tivozanib hydrochloride vs sorafenib on health-related quality of life among patients with advanced/metastatic renal cell carcinoma (mRCC): TIVO-1 study results